Company intelligence / Profile preview

Enzybel

Ownership: Private
Employees: ~24
Development stage: Commercial

Overview

Enzybel produces and supplies plant and animal-derived proteolytic enzymes such as bromelain, papain, ficin, chymotrypsin, trypsin and pancreatin. These are used globally in pharmaceuticals as APIs for inflammation/digestion support and in food/nutraceutical/cosmetic industries. The company holds GMP pharma certifications for its production sites. No clinical trial results reported.

Therapeutic areas: Metabolic DisordersOncologyImmunologyOtherDermatologyRheumatologyGastroenterology
Modalities: ProteinRecombinant proteinEnzyme replacement therapyBiologic
Industry: Chemicals & Materials

Partnerships

GGP Group

Beyond the preview

Go deeper on Enzybel.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enzybel.

Explore the full profile